Antidotes

HJF Receives Patent for Potential Treatment for Nerve Agent Exposure

Retrieved on: 
Tuesday, May 11, 2021
Drugs, Acetylcholinesterase inhibitors, Psychoactive drugs, Medicine, Antidotes, Nerve agent, Atropine, Organophosphate, Anticholinergic, Henry M. Jackson Foundation for the Advancement of Military Medicine, Autoinjector

b"BETHESDA, Md., May 11, 2021 /PRNewswire/ --The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) received notice of allowance for a patent from the United States Patent Office (USPO) for a medical countermeasure to organophosphate (OP) nerve agent exposure.

Key Points: 
  • b"BETHESDA, Md., May 11, 2021 /PRNewswire/ --The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) received notice of allowance for a patent from the United States Patent Office (USPO) for a medical countermeasure to organophosphate (OP) nerve agent exposure.
  • The therapy was shown to be effective even with delayed use following nerve agent exposure.
  • Currently, treatment for OP exposure is with an anticholinergic agent administered immediately after exposure; thus, military personnel may receive kits containing atropine auto-injectors for use in the event of a nerve-gas attack.\nDr.
  • Importantly, this new combination therapy also extends the therapeutic window, as it is effective even when administered hours after OP exposure.

Lobe Sciences Successfully Completes Proof-of-Concept of Proprietary Nasal Mist Device

Retrieved on: 
Thursday, February 18, 2021
Medicine, Clinical medicine, Drugs, Dosage forms, Antidotes, Acetylcysteine, Antioxidants, Thiols, Treatment of bipolar disorder, Post-traumatic, Nasal spray, Dose

Proprietary spray delivers micro doses of psilocybin or N-acetylcysteine for treatment of PTSD and traumatic brain injury

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - February 18, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF)("Lobe" or the "Company") announced today the completion and testing of the proof-of-concept prototype of its proprietary nasal mist device.
  • Lobe's nasal mist device delivers "micro doses" of pharmaceutical agents such as a psilocybin and N-acetylcysteine ("NAC") at preselected dosages.
  • Completing the development of this device will enable the patients to easily treat themselves where they live and work."
  • Lobe holds several provisional patent applications, including the nasal mist device entitled "Device and Method for the Treatment of Traumatic Brain Injuries and Post-Traumatic Stress Disorder".

Growing Focus of Players toward Strengthening Their Product Portfolio Drives Anticoagulant Reversal Drugs Market Growth: TMR

Retrieved on: 
Thursday, January 28, 2021
Blood, Clinical medicine, Branches of biology, Coagulation system, Blood tests, Antidotes, Anticoagulant, Thrombin, Vitamin K, Idarucizumab, Prothrombin complex concentrate

Vitamin K, prothrombin complex concentrates, tranexamic acid, protamine, AndeXXa, and idarucizumab are some of the products available in the global anticoagulant reversal drugs market .

Key Points: 
  • Vitamin K, prothrombin complex concentrates, tranexamic acid, protamine, AndeXXa, and idarucizumab are some of the products available in the global anticoagulant reversal drugs market .
  • Researchers at TMR are of the opinion that the global anticoagulant reversal drugs market will show growth at a whopping CAGR of 15.6% during assessment period 20182026.
  • Gain insights into the Anticoagulant Reversal Drugs Market (Product - Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, AndeXXa; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026 at https://www.transparencymarketresearch.com/report-toc/40970
    Many players in the global anticoagulant reversal drugs market are growing focus toward strengthening their product portfolio.
  • Major players working in the global anticoagulant reversal drugs market are growing efforts to fulfill the growing market demand.

Growing Focus of Players toward Strengthening Their Product Portfolio Drives Anticoagulant Reversal Drugs Market Growth: TMR

Retrieved on: 
Thursday, January 28, 2021
Blood, Clinical medicine, Branches of biology, Coagulation system, Blood tests, Antidotes, Anticoagulant, Thrombin, Vitamin K, Idarucizumab, Prothrombin complex concentrate

Vitamin K, prothrombin complex concentrates, tranexamic acid, protamine, AndeXXa, and idarucizumab are some of the products available in the global anticoagulant reversal drugs market .

Key Points: 
  • Vitamin K, prothrombin complex concentrates, tranexamic acid, protamine, AndeXXa, and idarucizumab are some of the products available in the global anticoagulant reversal drugs market .
  • Researchers at TMR are of the opinion that the global anticoagulant reversal drugs market will show growth at a whopping CAGR of 15.6% during assessment period 20182026.
  • Gain insights into the Anticoagulant Reversal Drugs Market (Product - Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, AndeXXa; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026 at https://www.transparencymarketresearch.com/report-toc/40970
    Many players in the global anticoagulant reversal drugs market are growing focus toward strengthening their product portfolio.
  • Major players working in the global anticoagulant reversal drugs market are growing efforts to fulfill the growing market demand.

Global Calcium Gluconate Industry (2020 to 2027) - Market Trajectory & Analytics - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 27, 2021
Health, Pharmaceutical, Chemistry, Physical sciences, Natural sciences, Calcium compounds, Antidotes, Calcium gluconate, Gluconates, Fluorine, Analytics, Calcium supplement

The "Calcium Gluconate - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Calcium Gluconate - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The 268-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.
  • This segment currently accounts for a 53.9% share of the global Calcium Gluconate market.
  • The country currently accounts for a 28.89% share in the global market.

Pacific Ethanol Completes Name Change to Alto Ingredients, Inc.

Retrieved on: 
Wednesday, January 13, 2021
Alcohols, Antidotes, Antiseptics, Disinfectants, Hepatotoxins, Medicine, Clinical medicine, Branches of biology

SACRAMENTO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Pacific Ethanol, Inc. (NASDAQ: PEIX), a leading producer of specialty alcohols and essential ingredients, has changed its corporate name to Alto Ingredients, Inc., effective January 12, 2021.

Key Points: 
  • SACRAMENTO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Pacific Ethanol, Inc. (NASDAQ: PEIX), a leading producer of specialty alcohols and essential ingredients, has changed its corporate name to Alto Ingredients, Inc., effective January 12, 2021.
  • Alto Ingredients, Inc. (PEIX), formerly known as Pacific Ethanol, Inc., is a leading producer of specialty alcohols and essential ingredients.
  • Such forward-looking statements include, but are not limited to, statements concerning Alto Ingredients' plans, objectives, expectations and intentions.
  • Actual results may differ materially from Alto Ingredients' current expectations depending upon a number of factors affecting Alto Ingredients' business.

EDTA Releases EV Leadership Plan, Praises COVID Relief Bill

Retrieved on: 
Tuesday, December 22, 2020
Amines, Antidotes, Ethylenediaminetetraacetic acid, Preservatives, Chemistry, Physical sciences, Chemical substances

EDTA President Genevieve Cullen said, The relief package includes essential relief for people and businesses in need and it contains important policy measures that will strengthen the U.S. electric drive industry at a critical time.

Key Points: 
  • EDTA President Genevieve Cullen said, The relief package includes essential relief for people and businesses in need and it contains important policy measures that will strengthen the U.S. electric drive industry at a critical time.
  • Cullen continued, Our EV Leadership Plan provides the policy blueprint to ensure U.S. leadership in electrified transportation technologies for the next century.
  • EDTA strongly supports the incoming Administrations commitment to U.S. leadership in electrification and the associations roadmap details how it can be achieved.
  • EDTA looks forward to working with all the supporters of U.S. leadership to build the future of mobility.

Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing

Retrieved on: 
Thursday, December 10, 2020
Drugs, Antidotes, Ketones, Morphinans, Naloxone, Konstantinidis, Chemistry, Chemical compounds

Under the Agreement, Opiant will be able to draw up to $50 million in three tranches.

Key Points: 
  • Under the Agreement, Opiant will be able to draw up to $50 million in three tranches.
  • This financing, together with the $31.1 million of cash on our balance sheet, provides Opiant with the financial flexibility to potentially launch OPNT003 without the need for additional financing, said Roger Crystal, M.D., President and Chief Executive Officer of Opiant.
  • Kreos is pleased to provide this financing to Opiant, said Aris Constantinides, partner at Kreos Capital.
  • Opiant Pharmaceuticals, Inc., the company that developed NARCAN Nasal Spray, is building a leadingfranchiseof new medicines to combat addictions and drug overdose.

2020: A Year Defined by Crisis and Nonstop Crisis Response

Retrieved on: 
Tuesday, November 17, 2020
Drugs, Psychoactive drugs, Medicine, Antidotes, Ketones, Morphinans, Naloxone, Opioid epidemic in the United States, Opioid, Drug overdose, Direct Relief, Vial

In response to the unrelenting catastrophes, Direct Relief in 2020 worked on more fronts than ever before in its 72-year history.

Key Points: 
  • In response to the unrelenting catastrophes, Direct Relief in 2020 worked on more fronts than ever before in its 72-year history.
  • Direct Relief's early identification of expected intensive care medication needs made it an important source of scarce medications during the worst phase of the crisis.
  • In response, Direct Relief has provided affected communities from Texas to South Carolina with more than $6 million in emergency aid.
  • Opioid Crisis: Direct Relief, with support from Pfizer, provided594,000 vials of the overdose reversal drug naloxone to recipients in 46 U.S. states.

Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S.

Retrieved on: 
Monday, September 28, 2020
FDA, Genetics, Clinical trials, Practice Management, Biotechnology, Other Health, Managed care, Health, Pharmaceutical, Clinical medicine, Medicine, Medical specialties, Transfusion reactions, Transfusion hemosiderosis, Transfusion medicine, Antidotes, Chelating agents, Deferiprone, RTT, Iron overload, Thalassemia

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today announced the launch of a new specialty generic, deferiprone, an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.

Key Points: 
  • Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today announced the launch of a new specialty generic, deferiprone, an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
  • At launch, Taros deferiprone tablets will be exclusively dispensed by BioPlus Specialty Pharmacy.
  • Deferiprone is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
  • Deferiprone is contraindicated in patients with known hypersensitivity to deferiprone or to any of the excipients in the formulation.